SlideShare a Scribd company logo
Institutional Review Board
Presented by
Mohammad Asim
Mpharm 1st year
Department of Pharmaceutics
Dipsar
INTRODUCTION
 Experimentation on human being is subject to ethical standards that promote
respect for all and protect their health and rights.
Research requiring ethical review:
 Research involving living human subjects and use of their medical records.
 Research involving human remains, cadavers, biological fluids, tissues,
embryos, fetuses and etc.
INTRODUCTION
 The “Institutional Review Board” (IRB) is a local administrative body
established to protect the rights, safety, and well-being of human research
subjects recruited to participate in a clinical research.
 The IRB has the authority to approve, require modification in, or disapprove
all research activities that fall within its jurisdiction.
 The IRB provides assurances to research subjects that every reasonable
attempt has been made to protect their rights and safety as subjects.
CONSTITUTION OF IRB
 The IRB should consist at least SEVEN members, who collectively have the qualifications and
experience to review and evaluate the science, medical aspects, and ethics of the proposed trial.
viz.
1. Chairperson – Appointed (who is from outside the institution)
2. 1-2 basic medical scientists
3. 1-2 clinicians from various institutes
4. One legal expert or retired judge
5. One social scientist
6. One philosopher or ethicist
7. One lay person from community
8. Member secretary – Appointed
QUORUM OF IRB
 For reviewing and making decision on each protocol the quorum of IRB should
be atleast FIVE members with the following representations:
1. Basic medical scientists (preferably one pharmacologist)
2. Clinicians
3. Legal expert
4. Social scientist / Representative of non-governmental voluntary agency /
Philosopher / Ethicist / Theologian or a similar person
5. Lay person from the community
QUORUM OF IRB
 In any case, the IRB must include
a) at least one member whose primary area of interest / specialization is
nonscientific
b) at least one member who is independent of the institution / trial site
 Besides, there should be appropriate gender representation on the IRB.
 If required, Subject experts may be invited to offer their views.
 Further, based on the requirement of research area, e.g. AIDS, genetic
disorders etc. specific patient groups may also be represented in the IRB.
FUNCTIONS AND OPERATIONS OF IRB
 Only those IRB members who are independent of the clinical trial and the
Sponsor of the trial should vote / provide opinion in matters related to the
study.
 Only members who participate in the IRB/IEC review and discussion should
vote/provide their opinion and/or advise.
 The IRB should perform its functions according to written standard operating
procedures, should maintain written records of its activities and minutes of
its meetings, and should comply with GCP and with the applicable regulatory
requirement(s).
FUNCTIONS AND OPERATIONS OF IRB
 The investigator may provide information on any aspect of the trial, but
should not participate in the deliberations of the IRB or in the vote/opinion of
the IRB.
 The IRB should establish, document in writing, and follow its procedures,
which should include
 Determining its composition (names and qualifications of the members)
 Scheduling, notifying its members of, and conducting its meetings
 Conducting initial and continuing review of trials
 Determining the frequency of continuing review, as appropriate
FUNCTIONS AND OPERATIONS OF IRB
 Specifying that no subject should be admitted to a trial before the IRB issues
its written approval / favorable opinion of the trial.
 Specifying that no deviations from, or changes of, the protocol should be
initiated without prior written IRB approval / favorable opinion of an
appropriate amendment, except when necessary to eliminate immediate
hazards to the subjects or when the change(s) involves only logistical or
administrative aspects of the trial.
FUNCTIONS AND OPERATIONS OF IRB
 Specifying that the investigator should promptly report to the IRB.
 Deviations from, or changes of, the protocol to eliminate immediate hazards
to the trial subjects.
 Changes increasing the risk to subjects and/or affecting significantly the
conduct of the trial.
 All adverse drug reactions (ADRs) that are both serious and unexpected.
 New information that may affect adversely the safety of the subjects or the
conduct of the trial
FUNCTIONS AND OPERATIONS OF IRB
 Ensuring that the IRB promptly notify in writing the investigator/institution
concerning.
 Its trial-related decisions/opinions .
 The reasons for its decisions/opinions.
 Procedures for appeal of its decisions/opinions
RESPONSIBILITIES OF IRB
 An IRB should safeguard the rights, safety, and well- being of all trial subjects.
 The IRB should obtain the following documents.
 Trial protocol(s)/amendment(s) Written informed consent form(s).
 Subject recruitment procedures (e.g.: Advertise).
 Written information to be provided to subjects.
 Investigator’s Brochure (IB).
 Available safety information.
 Information about payments and compensation.
 Investigator’s current curriculum vitae.
 Any other may need to fulfill its responsibilities.
RESPONSIBILITIES OF IRB
 The IRB should review a proposed clinical trial within a reasonable time and
document its views in writing, clearly identifying the trial, the documents
reviewed and the dates for the following.
 Approval / favourable opinion.
 modifications required prior to its approval / favourable opinion;
 disapproval / negative opinion
 Termination / suspension of any prior approval / favourable opinion
 The IRB should consider the qualifications of the investigator for the proposed
trial, as documented by a current curriculum vitae and / or by any other
relevant documentation the IRB requests.
RESPONSIBILITIES OF IRB
 The IRB/IEC should conduct continuing review of each ongoing trial at
intervals appropriate to the degree of risk to human subjects, but at least
once per year.
 The IRB may request more information than is given to study subjects when,
in the judgement of the IRB the additional information would add meaning to
the protection of the rights, safety and/or well-being of the subjects.
 The IRB should review both the amount and method of payment to subjects to
assure neither compulsion nor undue influence on the trial subjects.
RESPONSIBILITIES OF IRB
 Payments to a subject should be prorated (day basis) and not wholly
contingent on completion of the trial by the subject.
 The IRB should ensure that information regarding payment to subjects,
including the methods, amounts, and schedule of payment to trial subjects, is
set forth in the written informed consent form and any other written
information to be provided to subjects
INFORMED CONSENT FORM
 A major component of GCP is the method by which the researchers will obtain
voluntary and informed consent from subjects
 Informed consent is a process, not just a form
 Information must be presented to enable persons to voluntarily decide
whether or not to participate as a research subject
 The procedures used in obtaining informed consent should be designed to
educate the subject population in terms that they can understand
INFORMED CONSENT FORM
 In seeking informed consent the following information should be provided to
the subject
 Statement that the study involves research and explanation of the purpose of
the research
 Expected duration of the Subject's participation
 Description of the procedures to be followed, including all invasive
procedures and
 Description of any reasonably foreseeable risks or discomforts to the Subject
 Description of any benefits to the Subject or others reasonably expected from
research. If no benefit is expected Subject should be made aware of this.
INFORMED CONSENT FORM
 Disclosure of specific appropriate alternative procedures or therapies
available to the Subject
 Statement describing the extent to which confidentiality of records
identifying the subject will be maintained and who will have access to
subject's medical records
 Trial treatment schedule(s) and the probability for random assignment to
each treatment (for randomized trials)
 Compensation and/or treatment(s) available to the Subject in the event of a
trial related injury
INFORMED CONSENT FORM
 An explanation about whom to contact for trial related queries, rights of
Subjects and in the event of any injury
 The anticipated prorated payment, if any, to the Subject for participating in
the trial
 Subject's responsibilities on participation in the trial
 Statement that participation is voluntary, that the subject can withdraw from
the study at any time and that refusal to participate will not involve any
penalty or loss of benefits to which the Subject is otherwise entitled
INFORMED CONSENT FORM
 Any other pertinent information which may be required, viz.
a. Statement of foreseeable circumstances under which the subject's participation may be
terminated by the investigator without the subject's consent
b. Additional costs to the subject that may result from participation in the study
c. The consequences of a subject's decision to withdraw from the research and procedures for
orderly termination of participation by subject
d. Statement that the subject or subject's representative will be notified in a timely manner if
significant new findings develop during the course of the research which may affect the subject's
willingness to continue participation will be provided
e. A statement that the particular treatment or procedure may involve risks to the subject (or to the
embryo or fetus, if the subject is or may become pregnant), which are currently unforeseeable
f. Approximate number of Subjects enrolled in the study
FORMAT OF INFORMED CONSENT FORM
Informed Consent Form To Participate In A Clinical Trial
Study Title:
Study Number:
Subject's Initials: _____________
Subject's Name:_______________
Date of Birth / Age: _________________
FORMAT OF INFORMED CONSENT FORM
Please initial in boxes:
1. I am above 18 years old [ ]
2. I confirm that I have read and understood the information sheet dated
_____ for the above study and have had the opportunity to ask questions [
]
3. I understand that my participation in the study is voluntary and that I am
free to withdraw at any time, without giving any reason, without my
medical care or legal rights being affected [ ]
4. I agree not to restrict the use of any data or results that arise from this
study provided such a use is only for scientific purpose(s) [ ]
FORMAT OF INFORMED CONSENT FORM
Please initial in boxes:
………………………..
……………………
5.I agree to take part in the above study
Signature (or Thumb impression) of the Subject/Legally Acceptable
Representative: ____________________
Date:__/__/__ Signatory's Name: ____________ Signature
of the Investigator:_______ Date: __/__/__
FORMAT OF INFORMED CONSENT FORM
Study Investigator's Name:_______________
Signature of the Witness________
Date:__ /__ /__
Name of the Witness:_______________________

More Related Content

What's hot

INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
Turacoz Skill Development Program
 
Informed consent process and procedures
Informed consent process and proceduresInformed consent process and procedures
Informed consent process and procedures
Siddu K M
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
Suhas Reddy C
 
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
ClinosolIndia
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
Manish Rajput
 
Investigator brochure
Investigator brochureInvestigator brochure
Investigator brochure
kanchangupta66
 
Safety monitoring in clinical trails
Safety monitoring in clinical trailsSafety monitoring in clinical trails
Safety monitoring in clinical trails
GOURIPRIYA L S
 
Clinical trail protocol and development
Clinical trail protocol and developmentClinical trail protocol and development
Clinical trail protocol and development
ChintamBaladattaSai
 
Cdsco ppt
Cdsco pptCdsco ppt
Cdsco ppt
Nikhat Sheikh
 
ICH GCP
ICH GCPICH GCP
Protocol development
Protocol developmentProtocol development
Protocol development
Alisha Bansal
 
IRB - ICF - PROTOCOL
IRB - ICF - PROTOCOLIRB - ICF - PROTOCOL
IRB - ICF - PROTOCOL
Suman Baishnab
 
Investigational new drug application
Investigational new drug application Investigational new drug application
Investigational new drug application
Kirsha K S
 
Contract Research Organisations- CRO in Pharma Field
Contract Research Organisations- CRO in Pharma FieldContract Research Organisations- CRO in Pharma Field
Contract Research Organisations- CRO in Pharma Field
VINOTH R
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.
Aakashdeep Raval
 
CLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOLCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL
Jayvantika Raulji
 
PMS (post marketing surveillance)
PMS (post marketing surveillance)PMS (post marketing surveillance)
PMS (post marketing surveillance)
SANDEEP LOHMOR
 
Informed consent process
Informed consent processInformed consent process
Informed consent process
DeveraneniVinay
 
Ind (investigational new drug application) and nda
Ind (investigational new drug application) and ndaInd (investigational new drug application) and nda
Ind (investigational new drug application) and nda
swati2084
 
Schedule y
Schedule ySchedule y

What's hot (20)

INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
 
Informed consent process and procedures
Informed consent process and proceduresInformed consent process and procedures
Informed consent process and procedures
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
Investigator brochure
Investigator brochureInvestigator brochure
Investigator brochure
 
Safety monitoring in clinical trails
Safety monitoring in clinical trailsSafety monitoring in clinical trails
Safety monitoring in clinical trails
 
Clinical trail protocol and development
Clinical trail protocol and developmentClinical trail protocol and development
Clinical trail protocol and development
 
Cdsco ppt
Cdsco pptCdsco ppt
Cdsco ppt
 
ICH GCP
ICH GCPICH GCP
ICH GCP
 
Protocol development
Protocol developmentProtocol development
Protocol development
 
IRB - ICF - PROTOCOL
IRB - ICF - PROTOCOLIRB - ICF - PROTOCOL
IRB - ICF - PROTOCOL
 
Investigational new drug application
Investigational new drug application Investigational new drug application
Investigational new drug application
 
Contract Research Organisations- CRO in Pharma Field
Contract Research Organisations- CRO in Pharma FieldContract Research Organisations- CRO in Pharma Field
Contract Research Organisations- CRO in Pharma Field
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.
 
CLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOLCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL
 
PMS (post marketing surveillance)
PMS (post marketing surveillance)PMS (post marketing surveillance)
PMS (post marketing surveillance)
 
Informed consent process
Informed consent processInformed consent process
Informed consent process
 
Ind (investigational new drug application) and nda
Ind (investigational new drug application) and ndaInd (investigational new drug application) and nda
Ind (investigational new drug application) and nda
 
Schedule y
Schedule ySchedule y
Schedule y
 

Similar to institutional review board and independent ethics committee

IRB (1).pdf
IRB (1).pdfIRB (1).pdf
IRB (1).pdf
HarshitaGaur20
 
IRB (1).pptx
IRB (1).pptxIRB (1).pptx
IRB (1).pptx
HarshitaGaur20
 
Ethical review process, mk sharma
Ethical review process, mk sharmaEthical review process, mk sharma
Ethical review process, mk sharma
SHARDA UNIVERSITY
 
ich gcp
ich gcpich gcp
Investigators Responsibilities during Clinical trials
Investigators Responsibilities during Clinical trialsInvestigators Responsibilities during Clinical trials
Investigators Responsibilities during Clinical trials
BHAVYARAJAN2
 
Investigators Responsibilities
Investigators Responsibilities Investigators Responsibilities
Investigators Responsibilities
ClinosolIndia
 
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
amitsoni240
 
Institutional review board/Research and ethical committee
Institutional review board/Research and ethical committeeInstitutional review board/Research and ethical committee
Institutional review board/Research and ethical committee
MerrinJoseph1
 
Ich e6(r1)
Ich e6(r1)Ich e6(r1)
Ich e6(r1)
ManishaChauhan86
 
Institutional Review Board
Institutional Review Board Institutional Review Board
Institutional Review Board
SimranDhiman12
 
Role and responsibilities of investigators as per ich
Role and responsibilities of investigators as per ichRole and responsibilities of investigators as per ich
Role and responsibilities of investigators as per ich
Maniz Joshi
 
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRRINDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRR
sarwankumar4524
 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
sagartrivedi14
 
ICH-GCP AND THEIR DIFFIRENCES TO INDIAN CLINICAL TRIAL GUIDELINES
ICH-GCP AND THEIR DIFFIRENCES TO INDIAN CLINICAL TRIAL GUIDELINESICH-GCP AND THEIR DIFFIRENCES TO INDIAN CLINICAL TRIAL GUIDELINES
ICH-GCP AND THEIR DIFFIRENCES TO INDIAN CLINICAL TRIAL GUIDELINES
DR. RANJEET PRASAD
 
Assignment on Regulatory Prespectives of Clinical Trials
Assignment on Regulatory Prespectives of Clinical TrialsAssignment on Regulatory Prespectives of Clinical Trials
Assignment on Regulatory Prespectives of Clinical Trials
Deepak Kumar
 
ich gcp principles
ich gcp principlesich gcp principles
ich gcp principles
Rohit K.
 
4.Clinical Trail Protocal and IRB or IEC.pptx
4.Clinical Trail Protocal and IRB or IEC.pptx4.Clinical Trail Protocal and IRB or IEC.pptx
4.Clinical Trail Protocal and IRB or IEC.pptx
brahmaiahmph
 
Qi Irb Presentation
Qi Irb PresentationQi Irb Presentation
Qi Irb Presentation
hedavidson
 
CRP ppt Aadil.pptx
CRP ppt Aadil.pptxCRP ppt Aadil.pptx
CRP ppt Aadil.pptx
SiddharthShekharSing4
 
Good Clinical Practice
Good Clinical PracticeGood Clinical Practice
Good Clinical Practice
Med Bee
 

Similar to institutional review board and independent ethics committee (20)

IRB (1).pdf
IRB (1).pdfIRB (1).pdf
IRB (1).pdf
 
IRB (1).pptx
IRB (1).pptxIRB (1).pptx
IRB (1).pptx
 
Ethical review process, mk sharma
Ethical review process, mk sharmaEthical review process, mk sharma
Ethical review process, mk sharma
 
ich gcp
ich gcpich gcp
ich gcp
 
Investigators Responsibilities during Clinical trials
Investigators Responsibilities during Clinical trialsInvestigators Responsibilities during Clinical trials
Investigators Responsibilities during Clinical trials
 
Investigators Responsibilities
Investigators Responsibilities Investigators Responsibilities
Investigators Responsibilities
 
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
 
Institutional review board/Research and ethical committee
Institutional review board/Research and ethical committeeInstitutional review board/Research and ethical committee
Institutional review board/Research and ethical committee
 
Ich e6(r1)
Ich e6(r1)Ich e6(r1)
Ich e6(r1)
 
Institutional Review Board
Institutional Review Board Institutional Review Board
Institutional Review Board
 
Role and responsibilities of investigators as per ich
Role and responsibilities of investigators as per ichRole and responsibilities of investigators as per ich
Role and responsibilities of investigators as per ich
 
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRRINDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRR
 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
 
ICH-GCP AND THEIR DIFFIRENCES TO INDIAN CLINICAL TRIAL GUIDELINES
ICH-GCP AND THEIR DIFFIRENCES TO INDIAN CLINICAL TRIAL GUIDELINESICH-GCP AND THEIR DIFFIRENCES TO INDIAN CLINICAL TRIAL GUIDELINES
ICH-GCP AND THEIR DIFFIRENCES TO INDIAN CLINICAL TRIAL GUIDELINES
 
Assignment on Regulatory Prespectives of Clinical Trials
Assignment on Regulatory Prespectives of Clinical TrialsAssignment on Regulatory Prespectives of Clinical Trials
Assignment on Regulatory Prespectives of Clinical Trials
 
ich gcp principles
ich gcp principlesich gcp principles
ich gcp principles
 
4.Clinical Trail Protocal and IRB or IEC.pptx
4.Clinical Trail Protocal and IRB or IEC.pptx4.Clinical Trail Protocal and IRB or IEC.pptx
4.Clinical Trail Protocal and IRB or IEC.pptx
 
Qi Irb Presentation
Qi Irb PresentationQi Irb Presentation
Qi Irb Presentation
 
CRP ppt Aadil.pptx
CRP ppt Aadil.pptxCRP ppt Aadil.pptx
CRP ppt Aadil.pptx
 
Good Clinical Practice
Good Clinical PracticeGood Clinical Practice
Good Clinical Practice
 

More from MOHAMMAD ASIM

Introduction to Affinity Chromatography
Introduction to Affinity ChromatographyIntroduction to Affinity Chromatography
Introduction to Affinity Chromatography
MOHAMMAD ASIM
 
Dissolution parameters of a dosage form
Dissolution parameters of a dosage formDissolution parameters of a dosage form
Dissolution parameters of a dosage form
MOHAMMAD ASIM
 
Vaccine Delivery System
Vaccine Delivery SystemVaccine Delivery System
Vaccine Delivery System
MOHAMMAD ASIM
 
3 D printing technology in pharmaceutical drug delivery system
3 D printing technology in pharmaceutical drug delivery system3 D printing technology in pharmaceutical drug delivery system
3 D printing technology in pharmaceutical drug delivery system
MOHAMMAD ASIM
 
Barriers to Ocular Drug Delivery
Barriers to Ocular Drug DeliveryBarriers to Ocular Drug Delivery
Barriers to Ocular Drug Delivery
MOHAMMAD ASIM
 
Introduction to Telepharmacy
Introduction to TelepharmacyIntroduction to Telepharmacy
Introduction to Telepharmacy
MOHAMMAD ASIM
 
Buccal Drug Delivery System
Buccal Drug Delivery SystemBuccal Drug Delivery System
Buccal Drug Delivery System
MOHAMMAD ASIM
 
Ethosomes: formulation and particle size determination
Ethosomes: formulation and particle size determinationEthosomes: formulation and particle size determination
Ethosomes: formulation and particle size determination
MOHAMMAD ASIM
 
Biopharmaceutic considerations in drug product design
Biopharmaceutic considerations in drug product designBiopharmaceutic considerations in drug product design
Biopharmaceutic considerations in drug product design
MOHAMMAD ASIM
 
Computer simulation in pharmacokinetics and pharmacodynamics
Computer simulation in pharmacokinetics and pharmacodynamicsComputer simulation in pharmacokinetics and pharmacodynamics
Computer simulation in pharmacokinetics and pharmacodynamics
MOHAMMAD ASIM
 
Ethosomes - formulation and evaluation
Ethosomes - formulation and evaluationEthosomes - formulation and evaluation
Ethosomes - formulation and evaluation
MOHAMMAD ASIM
 
Clinical data collection and management
Clinical data collection and managementClinical data collection and management
Clinical data collection and management
MOHAMMAD ASIM
 
Microcapsules: types, preparation and evaluation
Microcapsules: types, preparation and evaluationMicrocapsules: types, preparation and evaluation
Microcapsules: types, preparation and evaluation
MOHAMMAD ASIM
 
Cosmetics - Biological aspects and design of cosmeceutical products
Cosmetics - Biological aspects and design of cosmeceutical productsCosmetics - Biological aspects and design of cosmeceutical products
Cosmetics - Biological aspects and design of cosmeceutical products
MOHAMMAD ASIM
 
Biosimilars and regulatory requirements for approval.
Biosimilars and regulatory requirements for approval.Biosimilars and regulatory requirements for approval.
Biosimilars and regulatory requirements for approval.
MOHAMMAD ASIM
 
Hair structure and hair growth cycle
Hair structure and hair growth cycleHair structure and hair growth cycle
Hair structure and hair growth cycle
MOHAMMAD ASIM
 
Common ingredients used in cosmetics
Common ingredients used in cosmeticsCommon ingredients used in cosmetics
Common ingredients used in cosmetics
MOHAMMAD ASIM
 
Common technical document (CTD) and electronic common technical document (eCTD)
Common technical document (CTD) and electronic common technical document (eCTD)Common technical document (CTD) and electronic common technical document (eCTD)
Common technical document (CTD) and electronic common technical document (eCTD)
MOHAMMAD ASIM
 

More from MOHAMMAD ASIM (18)

Introduction to Affinity Chromatography
Introduction to Affinity ChromatographyIntroduction to Affinity Chromatography
Introduction to Affinity Chromatography
 
Dissolution parameters of a dosage form
Dissolution parameters of a dosage formDissolution parameters of a dosage form
Dissolution parameters of a dosage form
 
Vaccine Delivery System
Vaccine Delivery SystemVaccine Delivery System
Vaccine Delivery System
 
3 D printing technology in pharmaceutical drug delivery system
3 D printing technology in pharmaceutical drug delivery system3 D printing technology in pharmaceutical drug delivery system
3 D printing technology in pharmaceutical drug delivery system
 
Barriers to Ocular Drug Delivery
Barriers to Ocular Drug DeliveryBarriers to Ocular Drug Delivery
Barriers to Ocular Drug Delivery
 
Introduction to Telepharmacy
Introduction to TelepharmacyIntroduction to Telepharmacy
Introduction to Telepharmacy
 
Buccal Drug Delivery System
Buccal Drug Delivery SystemBuccal Drug Delivery System
Buccal Drug Delivery System
 
Ethosomes: formulation and particle size determination
Ethosomes: formulation and particle size determinationEthosomes: formulation and particle size determination
Ethosomes: formulation and particle size determination
 
Biopharmaceutic considerations in drug product design
Biopharmaceutic considerations in drug product designBiopharmaceutic considerations in drug product design
Biopharmaceutic considerations in drug product design
 
Computer simulation in pharmacokinetics and pharmacodynamics
Computer simulation in pharmacokinetics and pharmacodynamicsComputer simulation in pharmacokinetics and pharmacodynamics
Computer simulation in pharmacokinetics and pharmacodynamics
 
Ethosomes - formulation and evaluation
Ethosomes - formulation and evaluationEthosomes - formulation and evaluation
Ethosomes - formulation and evaluation
 
Clinical data collection and management
Clinical data collection and managementClinical data collection and management
Clinical data collection and management
 
Microcapsules: types, preparation and evaluation
Microcapsules: types, preparation and evaluationMicrocapsules: types, preparation and evaluation
Microcapsules: types, preparation and evaluation
 
Cosmetics - Biological aspects and design of cosmeceutical products
Cosmetics - Biological aspects and design of cosmeceutical productsCosmetics - Biological aspects and design of cosmeceutical products
Cosmetics - Biological aspects and design of cosmeceutical products
 
Biosimilars and regulatory requirements for approval.
Biosimilars and regulatory requirements for approval.Biosimilars and regulatory requirements for approval.
Biosimilars and regulatory requirements for approval.
 
Hair structure and hair growth cycle
Hair structure and hair growth cycleHair structure and hair growth cycle
Hair structure and hair growth cycle
 
Common ingredients used in cosmetics
Common ingredients used in cosmeticsCommon ingredients used in cosmetics
Common ingredients used in cosmetics
 
Common technical document (CTD) and electronic common technical document (eCTD)
Common technical document (CTD) and electronic common technical document (eCTD)Common technical document (CTD) and electronic common technical document (eCTD)
Common technical document (CTD) and electronic common technical document (eCTD)
 

Recently uploaded

What is Packaging of Products in Odoo 17
What is Packaging of Products in Odoo 17What is Packaging of Products in Odoo 17
What is Packaging of Products in Odoo 17
Celine George
 
A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...
Association for Project Management
 
How to Manage Early Receipt Printing in Odoo 17 POS
How to Manage Early Receipt Printing in Odoo 17 POSHow to Manage Early Receipt Printing in Odoo 17 POS
How to Manage Early Receipt Printing in Odoo 17 POS
Celine George
 
How to Empty a One2Many Field in Odoo 17
How to Empty a One2Many Field in Odoo 17How to Empty a One2Many Field in Odoo 17
How to Empty a One2Many Field in Odoo 17
Celine George
 
"DANH SÁCH THÍ SINH XÉT TUYỂN SỚM ĐỦ ĐIỀU KIỆN TRÚNG TUYỂN ĐẠI HỌC CHÍNH QUY ...
"DANH SÁCH THÍ SINH XÉT TUYỂN SỚM ĐỦ ĐIỀU KIỆN TRÚNG TUYỂN ĐẠI HỌC CHÍNH QUY ..."DANH SÁCH THÍ SINH XÉT TUYỂN SỚM ĐỦ ĐIỀU KIỆN TRÚNG TUYỂN ĐẠI HỌC CHÍNH QUY ...
"DANH SÁCH THÍ SINH XÉT TUYỂN SỚM ĐỦ ĐIỀU KIỆN TRÚNG TUYỂN ĐẠI HỌC CHÍNH QUY ...
thanhluan21
 
How to Add a Filter in the Odoo 17 - Odoo 17 Slides
How to Add a Filter in the Odoo 17 - Odoo 17 SlidesHow to Add a Filter in the Odoo 17 - Odoo 17 Slides
How to Add a Filter in the Odoo 17 - Odoo 17 Slides
Celine George
 
How to Create & Publish a Blog in Odoo 17 Website
How to Create & Publish a Blog in Odoo 17 WebsiteHow to Create & Publish a Blog in Odoo 17 Website
How to Create & Publish a Blog in Odoo 17 Website
Celine George
 
Odoo 17 Social Marketing - Lead Generation On Facebook
Odoo 17 Social Marketing - Lead Generation On FacebookOdoo 17 Social Marketing - Lead Generation On Facebook
Odoo 17 Social Marketing - Lead Generation On Facebook
Celine George
 
BÀI TẬP BỔ TRỢ 4 KỸ NĂNG TIẾNG ANH LỚP 12 - GLOBAL SUCCESS - FORM MỚI 2025 - ...
BÀI TẬP BỔ TRỢ 4 KỸ NĂNG TIẾNG ANH LỚP 12 - GLOBAL SUCCESS - FORM MỚI 2025 - ...BÀI TẬP BỔ TRỢ 4 KỸ NĂNG TIẾNG ANH LỚP 12 - GLOBAL SUCCESS - FORM MỚI 2025 - ...
BÀI TẬP BỔ TRỢ 4 KỸ NĂNG TIẾNG ANH LỚP 12 - GLOBAL SUCCESS - FORM MỚI 2025 - ...
Nguyen Thanh Tu Collection
 
1. Importance_of_reducing_postharvest_loss.pptx
1. Importance_of_reducing_postharvest_loss.pptx1. Importance_of_reducing_postharvest_loss.pptx
1. Importance_of_reducing_postharvest_loss.pptx
UmeshTimilsina1
 
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptxSD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
elwoodprias1
 
modul ajar kelas x bahasa inggris 2024-2025
modul ajar kelas x bahasa inggris 2024-2025modul ajar kelas x bahasa inggris 2024-2025
modul ajar kelas x bahasa inggris 2024-2025
NurFitriah45
 
FINAL MATATAG Kindergarten CG 2023 pdf
FINAL MATATAG Kindergarten CG 2023   pdfFINAL MATATAG Kindergarten CG 2023   pdf
FINAL MATATAG Kindergarten CG 2023 pdf
maricelrudela
 
How to Manage Shipping Connectors & Shipping Methods in Odoo 17
How to Manage Shipping Connectors & Shipping Methods in Odoo 17How to Manage Shipping Connectors & Shipping Methods in Odoo 17
How to Manage Shipping Connectors & Shipping Methods in Odoo 17
Celine George
 
Kesadaran_Berbangsa_dan_Bernegara_Nasion.pptx
Kesadaran_Berbangsa_dan_Bernegara_Nasion.pptxKesadaran_Berbangsa_dan_Bernegara_Nasion.pptx
Kesadaran_Berbangsa_dan_Bernegara_Nasion.pptx
artenzmartenkai
 
Allopathic M1 Srudent Orientation Powerpoint
Allopathic M1 Srudent Orientation PowerpointAllopathic M1 Srudent Orientation Powerpoint
Allopathic M1 Srudent Orientation Powerpoint
Julie Sarpy
 
modul ajar kelas x bahasa inggris 24/254
modul ajar kelas x bahasa inggris 24/254modul ajar kelas x bahasa inggris 24/254
modul ajar kelas x bahasa inggris 24/254
NurFitriah45
 
Introduction to Banking System in India.ppt
Introduction to Banking System in India.pptIntroduction to Banking System in India.ppt
Introduction to Banking System in India.ppt
Dr. S. Bulomine Regi
 
Imagination in Computer Science Research
Imagination in Computer Science ResearchImagination in Computer Science Research
Imagination in Computer Science Research
Abhik Roychoudhury
 
Parent PD Design for Professional Development .docx
Parent PD Design for Professional Development .docxParent PD Design for Professional Development .docx
Parent PD Design for Professional Development .docx
AntonioJarligoCompra
 

Recently uploaded (20)

What is Packaging of Products in Odoo 17
What is Packaging of Products in Odoo 17What is Packaging of Products in Odoo 17
What is Packaging of Products in Odoo 17
 
A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...
 
How to Manage Early Receipt Printing in Odoo 17 POS
How to Manage Early Receipt Printing in Odoo 17 POSHow to Manage Early Receipt Printing in Odoo 17 POS
How to Manage Early Receipt Printing in Odoo 17 POS
 
How to Empty a One2Many Field in Odoo 17
How to Empty a One2Many Field in Odoo 17How to Empty a One2Many Field in Odoo 17
How to Empty a One2Many Field in Odoo 17
 
"DANH SÁCH THÍ SINH XÉT TUYỂN SỚM ĐỦ ĐIỀU KIỆN TRÚNG TUYỂN ĐẠI HỌC CHÍNH QUY ...
"DANH SÁCH THÍ SINH XÉT TUYỂN SỚM ĐỦ ĐIỀU KIỆN TRÚNG TUYỂN ĐẠI HỌC CHÍNH QUY ..."DANH SÁCH THÍ SINH XÉT TUYỂN SỚM ĐỦ ĐIỀU KIỆN TRÚNG TUYỂN ĐẠI HỌC CHÍNH QUY ...
"DANH SÁCH THÍ SINH XÉT TUYỂN SỚM ĐỦ ĐIỀU KIỆN TRÚNG TUYỂN ĐẠI HỌC CHÍNH QUY ...
 
How to Add a Filter in the Odoo 17 - Odoo 17 Slides
How to Add a Filter in the Odoo 17 - Odoo 17 SlidesHow to Add a Filter in the Odoo 17 - Odoo 17 Slides
How to Add a Filter in the Odoo 17 - Odoo 17 Slides
 
How to Create & Publish a Blog in Odoo 17 Website
How to Create & Publish a Blog in Odoo 17 WebsiteHow to Create & Publish a Blog in Odoo 17 Website
How to Create & Publish a Blog in Odoo 17 Website
 
Odoo 17 Social Marketing - Lead Generation On Facebook
Odoo 17 Social Marketing - Lead Generation On FacebookOdoo 17 Social Marketing - Lead Generation On Facebook
Odoo 17 Social Marketing - Lead Generation On Facebook
 
BÀI TẬP BỔ TRỢ 4 KỸ NĂNG TIẾNG ANH LỚP 12 - GLOBAL SUCCESS - FORM MỚI 2025 - ...
BÀI TẬP BỔ TRỢ 4 KỸ NĂNG TIẾNG ANH LỚP 12 - GLOBAL SUCCESS - FORM MỚI 2025 - ...BÀI TẬP BỔ TRỢ 4 KỸ NĂNG TIẾNG ANH LỚP 12 - GLOBAL SUCCESS - FORM MỚI 2025 - ...
BÀI TẬP BỔ TRỢ 4 KỸ NĂNG TIẾNG ANH LỚP 12 - GLOBAL SUCCESS - FORM MỚI 2025 - ...
 
1. Importance_of_reducing_postharvest_loss.pptx
1. Importance_of_reducing_postharvest_loss.pptx1. Importance_of_reducing_postharvest_loss.pptx
1. Importance_of_reducing_postharvest_loss.pptx
 
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptxSD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
 
modul ajar kelas x bahasa inggris 2024-2025
modul ajar kelas x bahasa inggris 2024-2025modul ajar kelas x bahasa inggris 2024-2025
modul ajar kelas x bahasa inggris 2024-2025
 
FINAL MATATAG Kindergarten CG 2023 pdf
FINAL MATATAG Kindergarten CG 2023   pdfFINAL MATATAG Kindergarten CG 2023   pdf
FINAL MATATAG Kindergarten CG 2023 pdf
 
How to Manage Shipping Connectors & Shipping Methods in Odoo 17
How to Manage Shipping Connectors & Shipping Methods in Odoo 17How to Manage Shipping Connectors & Shipping Methods in Odoo 17
How to Manage Shipping Connectors & Shipping Methods in Odoo 17
 
Kesadaran_Berbangsa_dan_Bernegara_Nasion.pptx
Kesadaran_Berbangsa_dan_Bernegara_Nasion.pptxKesadaran_Berbangsa_dan_Bernegara_Nasion.pptx
Kesadaran_Berbangsa_dan_Bernegara_Nasion.pptx
 
Allopathic M1 Srudent Orientation Powerpoint
Allopathic M1 Srudent Orientation PowerpointAllopathic M1 Srudent Orientation Powerpoint
Allopathic M1 Srudent Orientation Powerpoint
 
modul ajar kelas x bahasa inggris 24/254
modul ajar kelas x bahasa inggris 24/254modul ajar kelas x bahasa inggris 24/254
modul ajar kelas x bahasa inggris 24/254
 
Introduction to Banking System in India.ppt
Introduction to Banking System in India.pptIntroduction to Banking System in India.ppt
Introduction to Banking System in India.ppt
 
Imagination in Computer Science Research
Imagination in Computer Science ResearchImagination in Computer Science Research
Imagination in Computer Science Research
 
Parent PD Design for Professional Development .docx
Parent PD Design for Professional Development .docxParent PD Design for Professional Development .docx
Parent PD Design for Professional Development .docx
 

institutional review board and independent ethics committee

  • 1. Institutional Review Board Presented by Mohammad Asim Mpharm 1st year Department of Pharmaceutics Dipsar
  • 2. INTRODUCTION  Experimentation on human being is subject to ethical standards that promote respect for all and protect their health and rights. Research requiring ethical review:  Research involving living human subjects and use of their medical records.  Research involving human remains, cadavers, biological fluids, tissues, embryos, fetuses and etc.
  • 3. INTRODUCTION  The “Institutional Review Board” (IRB) is a local administrative body established to protect the rights, safety, and well-being of human research subjects recruited to participate in a clinical research.  The IRB has the authority to approve, require modification in, or disapprove all research activities that fall within its jurisdiction.  The IRB provides assurances to research subjects that every reasonable attempt has been made to protect their rights and safety as subjects.
  • 4. CONSTITUTION OF IRB  The IRB should consist at least SEVEN members, who collectively have the qualifications and experience to review and evaluate the science, medical aspects, and ethics of the proposed trial. viz. 1. Chairperson – Appointed (who is from outside the institution) 2. 1-2 basic medical scientists 3. 1-2 clinicians from various institutes 4. One legal expert or retired judge 5. One social scientist 6. One philosopher or ethicist 7. One lay person from community 8. Member secretary – Appointed
  • 5. QUORUM OF IRB  For reviewing and making decision on each protocol the quorum of IRB should be atleast FIVE members with the following representations: 1. Basic medical scientists (preferably one pharmacologist) 2. Clinicians 3. Legal expert 4. Social scientist / Representative of non-governmental voluntary agency / Philosopher / Ethicist / Theologian or a similar person 5. Lay person from the community
  • 6. QUORUM OF IRB  In any case, the IRB must include a) at least one member whose primary area of interest / specialization is nonscientific b) at least one member who is independent of the institution / trial site  Besides, there should be appropriate gender representation on the IRB.  If required, Subject experts may be invited to offer their views.  Further, based on the requirement of research area, e.g. AIDS, genetic disorders etc. specific patient groups may also be represented in the IRB.
  • 7. FUNCTIONS AND OPERATIONS OF IRB  Only those IRB members who are independent of the clinical trial and the Sponsor of the trial should vote / provide opinion in matters related to the study.  Only members who participate in the IRB/IEC review and discussion should vote/provide their opinion and/or advise.  The IRB should perform its functions according to written standard operating procedures, should maintain written records of its activities and minutes of its meetings, and should comply with GCP and with the applicable regulatory requirement(s).
  • 8. FUNCTIONS AND OPERATIONS OF IRB  The investigator may provide information on any aspect of the trial, but should not participate in the deliberations of the IRB or in the vote/opinion of the IRB.  The IRB should establish, document in writing, and follow its procedures, which should include  Determining its composition (names and qualifications of the members)  Scheduling, notifying its members of, and conducting its meetings  Conducting initial and continuing review of trials  Determining the frequency of continuing review, as appropriate
  • 9. FUNCTIONS AND OPERATIONS OF IRB  Specifying that no subject should be admitted to a trial before the IRB issues its written approval / favorable opinion of the trial.  Specifying that no deviations from, or changes of, the protocol should be initiated without prior written IRB approval / favorable opinion of an appropriate amendment, except when necessary to eliminate immediate hazards to the subjects or when the change(s) involves only logistical or administrative aspects of the trial.
  • 10. FUNCTIONS AND OPERATIONS OF IRB  Specifying that the investigator should promptly report to the IRB.  Deviations from, or changes of, the protocol to eliminate immediate hazards to the trial subjects.  Changes increasing the risk to subjects and/or affecting significantly the conduct of the trial.  All adverse drug reactions (ADRs) that are both serious and unexpected.  New information that may affect adversely the safety of the subjects or the conduct of the trial
  • 11. FUNCTIONS AND OPERATIONS OF IRB  Ensuring that the IRB promptly notify in writing the investigator/institution concerning.  Its trial-related decisions/opinions .  The reasons for its decisions/opinions.  Procedures for appeal of its decisions/opinions
  • 12. RESPONSIBILITIES OF IRB  An IRB should safeguard the rights, safety, and well- being of all trial subjects.  The IRB should obtain the following documents.  Trial protocol(s)/amendment(s) Written informed consent form(s).  Subject recruitment procedures (e.g.: Advertise).  Written information to be provided to subjects.  Investigator’s Brochure (IB).  Available safety information.  Information about payments and compensation.  Investigator’s current curriculum vitae.  Any other may need to fulfill its responsibilities.
  • 13. RESPONSIBILITIES OF IRB  The IRB should review a proposed clinical trial within a reasonable time and document its views in writing, clearly identifying the trial, the documents reviewed and the dates for the following.  Approval / favourable opinion.  modifications required prior to its approval / favourable opinion;  disapproval / negative opinion  Termination / suspension of any prior approval / favourable opinion  The IRB should consider the qualifications of the investigator for the proposed trial, as documented by a current curriculum vitae and / or by any other relevant documentation the IRB requests.
  • 14. RESPONSIBILITIES OF IRB  The IRB/IEC should conduct continuing review of each ongoing trial at intervals appropriate to the degree of risk to human subjects, but at least once per year.  The IRB may request more information than is given to study subjects when, in the judgement of the IRB the additional information would add meaning to the protection of the rights, safety and/or well-being of the subjects.  The IRB should review both the amount and method of payment to subjects to assure neither compulsion nor undue influence on the trial subjects.
  • 15. RESPONSIBILITIES OF IRB  Payments to a subject should be prorated (day basis) and not wholly contingent on completion of the trial by the subject.  The IRB should ensure that information regarding payment to subjects, including the methods, amounts, and schedule of payment to trial subjects, is set forth in the written informed consent form and any other written information to be provided to subjects
  • 16. INFORMED CONSENT FORM  A major component of GCP is the method by which the researchers will obtain voluntary and informed consent from subjects  Informed consent is a process, not just a form  Information must be presented to enable persons to voluntarily decide whether or not to participate as a research subject  The procedures used in obtaining informed consent should be designed to educate the subject population in terms that they can understand
  • 17. INFORMED CONSENT FORM  In seeking informed consent the following information should be provided to the subject  Statement that the study involves research and explanation of the purpose of the research  Expected duration of the Subject's participation  Description of the procedures to be followed, including all invasive procedures and  Description of any reasonably foreseeable risks or discomforts to the Subject  Description of any benefits to the Subject or others reasonably expected from research. If no benefit is expected Subject should be made aware of this.
  • 18. INFORMED CONSENT FORM  Disclosure of specific appropriate alternative procedures or therapies available to the Subject  Statement describing the extent to which confidentiality of records identifying the subject will be maintained and who will have access to subject's medical records  Trial treatment schedule(s) and the probability for random assignment to each treatment (for randomized trials)  Compensation and/or treatment(s) available to the Subject in the event of a trial related injury
  • 19. INFORMED CONSENT FORM  An explanation about whom to contact for trial related queries, rights of Subjects and in the event of any injury  The anticipated prorated payment, if any, to the Subject for participating in the trial  Subject's responsibilities on participation in the trial  Statement that participation is voluntary, that the subject can withdraw from the study at any time and that refusal to participate will not involve any penalty or loss of benefits to which the Subject is otherwise entitled
  • 20. INFORMED CONSENT FORM  Any other pertinent information which may be required, viz. a. Statement of foreseeable circumstances under which the subject's participation may be terminated by the investigator without the subject's consent b. Additional costs to the subject that may result from participation in the study c. The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by subject d. Statement that the subject or subject's representative will be notified in a timely manner if significant new findings develop during the course of the research which may affect the subject's willingness to continue participation will be provided e. A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant), which are currently unforeseeable f. Approximate number of Subjects enrolled in the study
  • 21. FORMAT OF INFORMED CONSENT FORM Informed Consent Form To Participate In A Clinical Trial Study Title: Study Number: Subject's Initials: _____________ Subject's Name:_______________ Date of Birth / Age: _________________
  • 22. FORMAT OF INFORMED CONSENT FORM Please initial in boxes: 1. I am above 18 years old [ ] 2. I confirm that I have read and understood the information sheet dated _____ for the above study and have had the opportunity to ask questions [ ] 3. I understand that my participation in the study is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected [ ] 4. I agree not to restrict the use of any data or results that arise from this study provided such a use is only for scientific purpose(s) [ ]
  • 23. FORMAT OF INFORMED CONSENT FORM Please initial in boxes: ……………………….. …………………… 5.I agree to take part in the above study Signature (or Thumb impression) of the Subject/Legally Acceptable Representative: ____________________ Date:__/__/__ Signatory's Name: ____________ Signature of the Investigator:_______ Date: __/__/__
  • 24. FORMAT OF INFORMED CONSENT FORM Study Investigator's Name:_______________ Signature of the Witness________ Date:__ /__ /__ Name of the Witness:_______________________